We searched Medline (1996–2008) and PubMed (1993–98), ClinicalTrials.gov, UpToDate database, and the National Cancer Institute Surveillance, Epidemiology and End Results Cancer Statistics Review 1975–2005. We used the search terms “bladder cancer”, “chemotherapy, bladder cancer”, “radiation therapy, bladder cancer”, “bladder presentation, cancer”, “invasive bladder cancer”, “neoadjuvant chemotherapy, bladder cancer”, “adjuvant chemotherapy, bladder cancer”, “chemotherapy, advanced bladder
SeminarBladder cancer
Section snippets
Epidemiology
Bladder cancer is the second most common genitourinary malignant disease in the USA, with an expected 69 000 newly diagnosed cases in 2008, and 14 000 deaths. The incidence of bladder cancer rises with age, peaking between age 50 years and 70 years, and is three times more common in men than in women.1 Risk factors for the development of bladder cancer can be classified into three subsets; genetic and molecular abnormalities, chemical or environmental exposures, and chronic irritation. Genetic
Pathophysiology and diagnosis
More than 90% of bladder cancers are transitional cell carcinomas, 5% are squamous cell carcinomas, and less than 2% are adenocarcinomas. The histopathological grading of transitional cell carcinoma of the bladder has historically been grade 1–3 as per the 1973 WHO classification system,17 but in 1998 a WHO and International Society of Urological Pathology consensus classified urothelial tumours into four categories; papilloma, papillary urothelial neoplasm of low malignant potential, low grade
Superficial bladder cancer
The high rate of recurrence is the feature of bladder cancer that makes follow-up a crucial component in effective management. After transurethral resection of the tumour, patients should have cystoscopy and voided urine cytology every 3 months for 2 years, then 6 monthly for 2 years, and then once yearly indefinitely. Upper tract imaging should be done every 12–24 months to establish whether a transitional cell carcinoma is present in the renal collecting system or ureters, because lifetime
Molecular biology and targeted therapies
Variations in chromosomal alterations arise at several points along the pathogenesis of transitional cell carcinoma. The loss of 9q seems to happen early in tumour development120 whereas the loss of 17p, 3p, 13q, 18q, and 10q is noted more frequently in high than in low grade and stage disease.121 When the range of genetic alterations in the pathogenesis of transitional cell carcinoma is compared, gains and amplifications are more frequent in advanced than in early stage disease, whereas
Search strategy and selection criteria
References (141)
- et al.
Loss of p63 expression is associated with tumor progression in bladder cancer
Am J Pathol
(2002) - et al.
Prognostic markers for bladder cancer: international consensus panel on bladder tumor markers
Urology
(2005) - et al.
Expression of cell cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder
Eur J Surg Oncol
(2003) - et al.
Natural history and treatment of low and high risk superficial bladder tumors
J Urol
(1988) - et al.
Current bladder tumor tests: does their projected utility fulfill clinical necessity?
J Urol
(2001) - et al.
Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence
Urology
(2001) ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma
Modern Pathology
(2005)- et al.
Urine markers for bladder cancer surveillance: a systematic review
Eur Urol
(2005) - et al.
Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?
J Urol
(2001) The value of second transurethral resection in evaluating patients with bladder tumors
J Urol
(1999)